31st May 2022 13:26
IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC submits 510(k) application to US Food & Drug Administration for IB Zero G, an artificial intelligence software that eliminates the need for gadolinium-based contrast agents in routine magnetic imagining exams. "The FDA 510(k) submission is the first step in potentially transforming the global gadolinium-based contrast agent market and introducing a paradigm shift in radiology departments," company says.
Current stock price: 4.35 pence, up 8.8% on Tuesday
12-month change: down 42%
By Abby Amoakuh; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
IQ-AI